Serving the Society Since 1986
Advanced Search
Volume 34 Issue 3
June 2019
    Citation: Daniel R. Lucey, Kristen R. Kent. Boosting Global Yellow Fever Vaccine Supply for Epidemic Preparedness: 3 Actions for China and the USA .VIROLOGICA SINICA, 2019, 34(3) : 235-239.  http://dx.doi.org/10.1007/s12250-019-00129-w
    shu

    Boosting Global Yellow Fever Vaccine Supply for Epidemic Preparedness: 3 Actions for China and the USA

    • 1.

      Department of Medicine-Infectious Diseases, Georgetown University Hospital, Washington, DC 20057, USA

    • 2.

      Medical School, Georgetown University School of Medicine, Washington, DC 20057, USA

    • Corresponding author: Daniel R. Lucey, DRL23@georgetown.edu, ORCID: 0000-0002-1027-1926
    • Received Date: 12 February 2019
      Accepted Date: 21 March 2019
      Published Date: 24 May 2019
      Available online: 01 June 2019
    • We advocate for three actions to be taken by the USA and China to help boost global supply of YF vaccine and increase epidemic preparedness and response. First, both nations would work with the WHO to have their YF vaccines prequalified. Thus, their vaccines could be used outside their own borders as part of the international stockpile of YF vaccine as traditionally administrated by the WHO, UNICEF and other members of the multi-partner International Coordinating Group. Second, production of this vaccine would be sharply scaled-up by both countries. These vaccines could be made available nationally, regionally, and globally through the ICG, e.g., to help stop and prevent epidemics anywhere in the world. Third, clinical studies would be coordinated with the WHO to assess the efficacy and safety of fractional dosing using 1/5 normal dose and if needed, even a 1/10 dose.
    • 加载中

      1. Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, Umutesi G, Laven J, Paluku G, Gueye AS, Hyde TB, Sheria GKM, Muyembe-Tanfum JJ, Staples JE (2018) Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—preliminary report. N Engl J Med. https://doi.org/10.1056/nejmoa1710430

      2. Baumgaertner E (2016) Could yellow fever become the next pandemic? Sci Am. https://www.scientificamerican.com/article/could-yellow-fever-become-the-next-pandemic/

      3. Brent SE, Watts A, Cetron M, German M, Kraemer MUG, Bogoch Ⅱ, Brady OJ, Hay SI, Creatore MI, Khan K (2018) International travel between global urban centres vulnerable to yellow fever transmission. Bull World Health Organ 96:343–354B
          doi: 10.2471/BLT.17.205658

      4. Brey PT, Fontenille D, Tang H (2018) Yellow fever risk in Asia-Pacific region. Nature 554:31

      5. Centers for Disease Control and Prevention (CDC) (2017) Clinical update announcement: temporary total depletion of US licensed yellow fever vaccine addressed by availability of Stamaril vaccine at selected clinics. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) and Division of Vector-Borne Diseases (DVBD). https://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-access

      6. Chen J, Lu H (2016) Yellow fever in China is still an imported disease. Biosci Trends 10:158–162
          doi: 10.5582/bst.2016.01051

      7. Chen Z, Liu L, Lv Y, Zhang W, Li J, Zhang Y, Di T, Zhang S, Liu J, Li J, Qu J, Hua W, Li C, Wang P, Zhang Q, Xu Y, Jiang R, Wang Q, Chen L, Wang S, Pang X, Liang M, Ma X, Li X, Wang Q, Zhang F, Li D (2016) A fatal yellow fever virus infection in China: description and lessons. Emerg Microbes Infect 5: e69

      8. Coyne P (2018) The World Health Organization Prequalification Programme—playing an essential role in assuring quality medical products. Royal Society of Tropical Medicine and Hygiene (International Health). https://doi.org/10.1093/inthealth/ihy/095

      9. de Menezes Martins R, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, de Albuquerque EM, Farias RHG, da Matta de Castro T, Homma A, Collaborative Group for Studies on Duration of Immunity from Yellow Fever Vaccine (2018) Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine 36:4112–4117
          doi: 10.1016/j.vaccine.2018.05.041

      10. Lucey DR, Donaldson H (2017) Yellow fever vaccine shortages in the United States and abroad: a critical issue. Ann Intern Med 167:664–666
          doi: 10.7326/M17-1337

      11. Lucey D, Gostin LO (2016) A yellow fever epidemic: a new global health emergency? JAMA 315:2661–2662
          doi: 10.1001/jama.2016.6606

      12. Martins RM, Maia Mde L, Farias RH, Camacho LA, Freire MS, Galler R, Yamamura AM, Almeida LF, Lima SM, Nogueira RM, Sá GR, Hokama DA, de Carvalho R, Freire RA, Pereira Filho E, Leal Mda L, Homma A (2013) 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 9:879–888
          doi: 10.4161/hv.22982

      13. Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, Heymann DL (2016) Yellow fever vaccine supply: a possible solution. Lancet 387:1599–1600
          doi: 10.1016/S0140-6736(16)30195-7

      14. Musso D, Parola P, Raoult D (2018) Yellow fever: the Pacific should be prepared. Lancet 392:2347

      15. Pan American Health Organization/World Health Organization (2018) Epidemiological update: yellow fever. 7 Dec 2018. PAHO/WHO, Washington, DC

      16. Pan American Health Organization/World Health Organization (2019) Epidemiological update: yellow fever. 25 Jan 2019. PAHO/WHO, Washington, DC

      17. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG (2008) Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 3:e1993
          doi: 10.1371/journal.pone.0001993

      18. Roukens AHE, van Halem K, de Visser AW, Visser LG (2018) Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med 169:761–766
          doi: 10.7326/M18-1529

      19. Schlagenhauf P, Chen LH (2017) Yellow fever importation to China—a failure of pre- and post-travel control systems? Int J Infect Dis 60:91–92
          doi: 10.1016/j.ijid.2017.06.003

      20. Shearer FM, Longbottom J, Browne AJ, Pigott DM, Brady OJ, Kraemer MUG, Marinho F, Yactayo S, de Araújo VEM, da Nóbrega AA, Fullman N, Ray SE, Mosser JF, Stanaway JD, Lim SS, Reiner RC Jr, Moyes CL, Hay SI, Golding N (2018) Existing and potential infection risk zones of yellow fever worldwide: a modelling analysis. Lancet Glob Health 6:e270–e278
          doi: 10.1016/S2214-109X(18)30024-X

      21. The Economist (2016) Yellow fever: a preventable tragedy. The Economist Newspaper Limited: Print edition, Leaders Editorial. https://www.economist.com/leaders/2016/05/14/a-preventable-tragedy

      22. Vannice K, Wilder-Smith A, Hombach J (2018) Fractional dose yellow fever vaccine—advancing the evidence base. N Engl J Med 379:603–605
          doi: 10.1056/NEJMp1803433

      23. Wang L, Zhou P, Fu X, Zheng Y, Huang S, Fang B, Zhang G, Jia K, Li S (2016) Yellow fever virus: increasing imported cases in China. J Infect 73:377–380
          doi: 10.1016/j.jinf.2016.07.003

      24. Wasserman S, Tambyah PA, Lim PL (2016) Yellow fever cases in Asia: primed for an epidemic. Int J Infect Dis 48:98–103
          doi: 10.1016/j.ijid.2016.04.025

      25. Wilder-Smith A, Leong WY (2017) Importation of yellow fever into China: assessing travel patterns. J Travel Med 24:1–4
          doi: 10.1093/jtm/tax018

      26. Wilder-Smith A, Massad E (2018) Estimating the number of unvaccinated Chinese workers against yellow fever in Angola. BMC Infect Dis 18:185
          doi: 10.1186/s12879-018-3084-y

      27. World Health Organization (WHO) (2013) Newly accessible Japanese encephalitis vaccine will make saving children easier in developing countries. https://www.who.int/mediacentre/news/releases/2013/japanese_encephalitis_20131009/en/

      28. World Health Organization (WHO) (2016a) Emergencies preparedness, response: yellow fever—China. WHO, Geneva. Disease Outbreak News. https://www.who.int/csr/don/22-april-2016-yellow-fever-china/en/

      29. World Health Organization (WHO) (2016b) Yellow Fever mass vaccination campaign using fractional dose in Kinshasa, DRC https://www.who.int/immunization/sage/meetings/2016/october/4_Yellow_fever_mass_vaccination_campaign_using_fractional_dose_in_Kinshasa.pdf

      30. World Health Organization (WHO) (2016c) Meeting of the Emergency Committee under the International Health Regulations (2005) concerning Yellow Fever. https://www.who.int/mediacentre/news/statements/2016/ec-yellow-fever/en/

      31. World Health Organization (WHO) (2016d) Global strategy to eliminate yellow fever epidemics (EYE). https://www.who.int/immunization/sage/meetings/2016/october/2_EYE_Strategy.pdf

      32. World Health Organization (WHO) (2016e) New yellow fever vaccination requirements for travelers. WHO, Geneva. International travel and health. https://www.who.int/ith/updates/20160727/en/

      33. World Health Organization (WHO) (2016f) Immunization standards: the WHO prequalification of vaccines procedure. WHO, Geneva. https://www.who.int/immunization_standards/vaccine_quality/pq_revision2010/en/

      34. World Health Organization (WHO) (2017a) Eliminate Yellow Fever Epidemics (EYE): a global strategy, 2017–2026. WHO, Geneva. https://apps.who.int/iris/bitstream/handle/10665/272408/9789241513661-eng.pdf?ua=1

      35. World Health Organization (WHO) (2017b) International Coordinating Group (ICG) on Vaccine Provision for Yellow Fever. Annual meeting, Geneva, 11–12 May 2017. https://www.who.int/csr/disease/icg/yellow-fever-may-2017/en/

      36. World Health Organization (WHO) (2018a) Immunization standards: vaccine PQ. WHO, Geneva. https://www.who.int/immunization_standards/vaccine_quality/vq_index/en/

      37. World Health Organization (WHO) (2018b) Yellow fever in Africa and the Americas, 2017. WHO, Geneva. https://apps.who.int/iris/bitstream/handle/10665/273782/WER9332.pdf?ua=1

      38. World Health Organization (WHO) (2018c) The second phase of Nigeria's biggest-ever yellow fever vaccination campaign gets underway. Regional Office for Africa. WHO, Geneva. http://afro.who.int/news/second-phase-nigerias-biggest-ever-yellow-fever-vaccination-campaign-gets-underway

    • 加载中

    Figures(2)

    PDF

    Article Metrics

    Article views(6233) PDF downloads(47) Cited by()

    Related
    Proportional views

      Boosting Global Yellow Fever Vaccine Supply for Epidemic Preparedness: 3 Actions for China and the USA

        Corresponding author: Daniel R. Lucey, DRL23@georgetown.edu
      • 1. Department of Medicine-Infectious Diseases, Georgetown University Hospital, Washington, DC 20057, USA
      • 2. Medical School, Georgetown University School of Medicine, Washington, DC 20057, USA
      • Received Date: 12 February 2019
      • Accepted Date: 21 March 2019
      • Published Date: 24 May 2019

      Abstract: We advocate for three actions to be taken by the USA and China to help boost global supply of YF vaccine and increase epidemic preparedness and response. First, both nations would work with the WHO to have their YF vaccines prequalified. Thus, their vaccines could be used outside their own borders as part of the international stockpile of YF vaccine as traditionally administrated by the WHO, UNICEF and other members of the multi-partner International Coordinating Group. Second, production of this vaccine would be sharply scaled-up by both countries. These vaccines could be made available nationally, regionally, and globally through the ICG, e.g., to help stop and prevent epidemics anywhere in the world. Third, clinical studies would be coordinated with the WHO to assess the efficacy and safety of fractional dosing using 1/5 normal dose and if needed, even a 1/10 dose.

        HTML